HUTCHMED (China) Limited (NASDAQ:HCM) Q2 2025 Earnings Conference Call August 7, 2025 8:00 AM ET
Company Participants
Chig Fung Cheng – CFO & Executive Director
David Ng – Head of Investor Relations & Capital Strategies
George Yuan – Corporate Participant
Ming Shi – Executive VP, Head of R&D and Chief Medical Officer
Wei-Guo Su – CEO, Chief Scientific Officer & Executive Director
Conference Call Participants
Chen Chen – UBS Investment Bank, Research Division
Matthew Yan – Unidentified Company
Paul Choi – Goldman Sachs Group, Inc., Research Division
David Ng
Hello, everyone. This is David Ng, Head of Investor Relations of HUTCHMED. Thank you for joining HUTCHMED 2025 Interim Result Presentation. Our result and presentation slides have already been posted on our homepage as well as on the Hong Kong Stock Exchange website.
Just a quick moment on the disclaimer. The performance and results of operation of HUTCHMED Group contained within this presentation are historical in nature, and past performance is no guarantee of future results, and actual results may vary materially from those set forth in the forward-looking statements.
So today, we are very glad to have our CEO, Dr. Su; our CFO, Mr. Cheng; our CMO, Dr. Shi; and our Head of Commercial, Mr. Yuan, to go over the results and provide the latest update on our performance and the projects under development. As usual, we will have a Q&A session at the very end [Operator Instructions].
So now let us welcome our Chief Executive Officer and Chief Scientific Officer, Dr. Wei-Guo Su to begin our presentation. Dr. Su?
Wei-Guo Su
Thank you, David.
If we go to the next slide. So again, good evening, good morning, everyone. Welcome to the HUTCHMED midyear result conference call. The highlights for the first half 2025. Global commercial success. FRUZAQLA continues to grow first half, up 25% comparing to 2024. ORPATHYS or savolitinib, potentially
#HUTCHMED #China #Limited #HCM #Earnings #Call #Transcript